Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes (Q83979505)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

0 references

1 reference

Ben-Xu Tan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Wen-Xiu Yao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Jun Ge

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Xing-Chen Peng

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Xiao-Bo Du

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ru Zhang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Bin Yao

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ke Xie

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Long-Hao Li

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hang Dong

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Feng Gao

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Feng Zhao

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Jian-Mei Hou

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Jing-Mei Su

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ji-Yan Liu

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

26 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

5103-5111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Diabetes and risk of breast cancer in Asian-American women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Re: Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Diabetes and risk of endometrial cancer: a population-based prospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.26151

1 reference

7 January 2021

Antidiabetic therapies affect risk of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Does diabetes therapy influence the risk of cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Long-term metformin use is associated with decreased risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin, B(12), and enhanced breast cancer response to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin as an addition to conventional chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Lung cancer in never smokers: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin therapy and clinical uses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

The AMP-activated protein kinase pathway--new players upstream and downstream.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Obesity and the role of adipose tissue in inflammation and metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Summaries for patients. Metformin for patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Prevention of pancreatic cancer induction in hamsters by metformin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Slowing the progression of renal disease in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Development of life-expectancy tables for people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Re: When you look matters: the effect of assessment schedule on progression-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

More clinical cancer treatments judged by progression-free rather than overall survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26151

7 January 2021

Identifiers

DOI

10.1002/CNCR.26151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523768%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference